Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers

• Main Authors: Thudium K (Author), Gallo J (Author), Bouillaud E (Author), Sachs C (Author), Eddy S (Author), Cheung W (Author)
• Format: Book
• Published: Dove Medical Press, 2015-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Karen Thudium,1 Jorge Gallo,2 Emmanuel Bouillaud,2 Carolin Sachs,2 Simantini Eddy,1 Wing Cheung1 1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 2Novartis Pharma AG, Basel, Switzerland Background: The mammalian target of rapamycin (mTOR) inhibitor everolimus has a well-established phar...